A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
about
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375.Desmoplastic small round cell tumor 20 years after its discovery.Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.
P2860
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@ast
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@en
type
label
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@ast
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@en
prefLabel
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@ast
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@en
P2093
P2860
P1476
A phase II study of tasisulam ...... etastatic soft tissue sarcoma.
@en
P2093
Antonio Lopez-Pousa
Chacon Matias
Charles Williams
Christopher Kaiser
Christopher W Ryan
Dinesh P de Alwis
M L Keohan
Mark Agulnik
Mary Alice Miller
Robert Ilaria
P2860
P2888
P304
P356
10.1007/S10637-012-9819-5
P577
2012-04-27T00:00:00Z
P6179
1003999228